{"filings":[{"id":610317,"accession_number":"0001688757-26-000044","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2026-05-22T20:29:55+00:00","items":["5.07","9.01"],"status":"ready","headline":"Establishment Labs annual meeting results: all directors elected, advisory pay approved, auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Seven directors elected with votes ranging from 17.3M to 20.0M; broker non-votes 3.1M.","Advisory vote on named executive officer compensation passed with 20.0M for, 30.5K against.","Ratification of CBIZ, CPAs P.C. as independent auditor for FY2026 approved with 22.7M for, 405.7K against.","No other proposals or material items presented at the May 22, 2026 meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94693,"accession_number":"0001688757-26-000038","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Establishment Labs Q1 revenue $59.9M (+44.7% YoY); raises FY guidance; adj. EBITDA positive for 3rd quarter","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $59.9M, up 44.7% YoY; US Motiva sales $19.6M (vs $6.2M Q1 2025).","Gross margin 70.7% (up from 67.2% YoY); operating loss narrowed to $6.5M from $16.9M.","Adjusted EBITDA of $1.2M vs loss of $12.1M YoY; cash balance $68.1M.","FY 2026 revenue guidance raised to $266.5M-$268.5M; minimally invasive revenue seen >$35M.","Expects free cash flow positive in H2 2026; reaffirms positive adjusted EBITDA each quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":59877000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94692,"accession_number":"0001688757-26-000033","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Establishment Labs enters up to $300M credit facility with Oaktree; repays ~$259M existing debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Tranche E Term Loan of $265M drawn April 30, 2026; optional Tranche F up to $35M.","Maturity April 30, 2031; interest rate 8.75% p.a. with PIK option and step-ups.","~$259M used to repay Prior Credit Agreement (April 2022) and transaction costs.","Financial covenants: minimum liquidity $30M and minimum gross sales test; equity cure available.","Existing subsidiaries guarantee obligations; customary covenants on additional debt, liens, M&A."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107270,"accession_number":"0001688757-26-000014","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Establishment Labs Q4 rev $64.6M (+45% YoY); guides 2026 rev $264-266M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2025 revenue $211.1M (+27.2% YoY); Q4 net loss $3.9M vs $18.7M loss a year ago.","Q4 adjusted EBITDA positive $5.5M vs ($13.1M) YoY; cash balance $75.6M at Dec 31, 2025.","Motiva U.S. Q4 revenue $17.3M; full year U.S. revenue $45.6M.","2026 revenue guidance $264-266M (+25-26% YoY); 2027 revenue growth projected at least 25%.","CEO cites Preservé product driving market expansion and expects first positive cash flow quarter in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":211076000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107269,"accession_number":"0001688757-26-000008","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2026-01-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Presentation at J.P. Morgan conference; no financial updates disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Furnished presentation materials for J.P. Morgan Healthcare Conference on Jan 14, 2026.","No specific financial data, guidance changes, or operational updates included in filing.","Exhibit 99.1 presentation not appended; cannot extract substantive details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107268,"accession_number":"0001688757-26-000004","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Establishment Labs expects Q4 revenue $64M-$65M; FY 2025 up 27% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue expected $64.0M-$65.0M, including $17.0M-$17.5M from Motiva US sales.","FY 2025 revenue expected $210.5M-$211.5M, ~27% growth over 2024; Motiva US $45.4M-$45.9M.","Year-end cash ~$75.5M, increase of $4.8M from Q3 2025.","Positive adjusted EBITDA; expects free cash flow positive later in 2026.","Preliminary unaudited results; full FY2025 results on February earnings call."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":211076000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123614,"accession_number":"0001628280-25-049261","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Establishment Labs Q3 revenue $53.8M (+33.8% YoY), positive Adj. EBITDA, raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $53.8M, up 33.8% YoY; US Motiva sales $11.9M.","Gross margin 70.1% vs 63.9% YoY; operating loss narrowed to $4.0M from $13.1M.","Adjusted EBITDA positive $1.2M vs loss of $7.0M in Q3 2024.","FY 2025 revenue guidance raised to >$210M from prior $208-212M.","Cash $70.6M; cash burn improved to $8.5M from $14.9M YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":146459000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123613,"accession_number":"0001688757-25-000062","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Establishment Labs amends credit agreement, draws $25M Tranche D term loans","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Fourth Amendment allows immediate availability of $25M Tranche D Term Loans, waiving revenue milestone.","Minimum liquidity requirement increased from $25M to $30M effective Sept 28, 2025.","Company fully drew $25M Tranche D Term Loans on Sept 29, 2025.","Amendment with Oaktree and other lenders to existing Credit Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140299,"accession_number":"0001688757-25-000054","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Establishment Labs Q2 revenue $51.3M (+16% YoY); raises FY2025 guidance to $208-212M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $51.3M, up 16.3% YoY; US Motiva sales $10.3M.","FY2025 revenue guidance raised to $208-212M from $205-210M; US Motiva revenue at least $40M.","Gross margin 68.8% vs 65.6% YoY; adjusted EBITDA loss $8.5M vs $4.1M.","Net loss $16.6M vs $17.2M; cash $54.6M plus $25M credit line.","CEO: on track for positive EBITDA in 2025, cash flow positive in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":92677000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157951,"accession_number":"0001688757-25-000050","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Motiva USA update: >1,000 surgeons, Q2 sales guide $9.5-10M, reconstruction filing Q4 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Over 1,000 surgeons now offer Motiva implants in the United States.","Q2 2025 Motiva US sales expected $9.5M–$10M (partial quarter).","Company to seek US FDA approval for Motiva reconstruction use in Q4 2025.","Preservé US launch anticipated in first half of 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157950,"accession_number":"0001688757-25-000045","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2025-05-27T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Shareholders re-elect all director nominees; Bryan Slotkin receives 92% for","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All four director nominees elected: Chacón Quirós, Custin, Lewin, Schutter each received >21.4M for; Slotkin 19.9M for, 1.7M against.","Advisory vote on executive compensation passed with 21.6M for, 56k against, 4.1M broker non-votes.","Ratification of CBIZ as independent auditor for FY2025 passed with 25.7M for, 38k against.","Meeting held May 23, 2025; all proposals approved with strong majorities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157949,"accession_number":"0001688757-25-000044","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["4.01","8.01","9.01"],"status":"ready","headline":"Establishment Labs replaces auditor Marcum with CBIZ after acquisition of attest business","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum resigned May 20, 2025; Audit Committee appointed CBIZ same day for FY 2025.","No disagreements or reportable events other than a previously disclosed material weakness in ITGC for FY 2023.","Marcum's audit reports for FY 2024 and 2023 were unqualified.","Company filed proxy supplement to reflect CBIZ as auditor for ratification vote at May 23 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157948,"accession_number":"0001688757-25-000036","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Establishment Labs Q1 revenue $41.4M, net loss $20.7M; appoints Peter Caldini CEO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $41.4M (up from $37.2M YoY); net loss $20.7M vs $16.2M loss in prior year.","Gross margin improved to 67.2% from 65.6%, driven by geographic mix and higher ASPs.","Adjusted EBITDA loss $12.1M; cash $69.2M, down $21.2M from year-end 2024.","FY 2025 revenue guidance reaffirmed at $205-210M (23-26% YoY growth).","Peter Caldini appointed CEO effective May 7, 2025; also launched Preservé platform."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":41377000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157947,"accession_number":"0001688757-25-000034","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Establishment Labs appoints Peter Caldini as permanent CEO, effective May 7, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Caldini had served as interim CEO since March 1, 2025, following founder Juan José Chacón-Quirós's retirement.","He will also fill the Class II director vacancy created by the death of director Dennis Condon, term expiring at 2026 AGM.","No change in Caldini's compensation; he will not receive extra director compensation as an employee.","Chairman Nick Lewin emphasized execution goals: turning EBITDA positive in 2025 and cash flow positive in 2026.","Founder Chacón-Quirós remains on the board and will continue supporting R&D and product adoption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157946,"accession_number":"0001688757-25-000022","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2025-04-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Establishment Labs reports preliminary Q1 revenue $41.4M, reiterates 2025 guidance $205-210M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q1 2025 revenue ~$41.4M, including ~$6.2M US Motiva sales.","Reaffirms 2025 revenue guidance $205-210M; expects EBITDA positive in 2025 and cash flow positive in 2026.","Tariffs impact less than 50 bps gross margin; no disruption from recent events.","Average daily orders in March surpassed 100; US launch accelerating.","Investor Day scheduled for June 12, 2025 in NYC; live webcast available."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":41377000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176336,"accession_number":"0001688757-25-000011","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Establishment Labs Q4 revenue $44.5M; reaffirms 2025 guidance of $205-210M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $44.5M (+41% YoY); gross margin 68.5% (up from 65.2%).","Net loss from operations $18.7M (improved from $22.1M); adj EBITDA loss $13.1M (from $17.4M).","U.S. Motiva launch: Q4 revenue $3.3M; Q1 2025 U.S. revenue expected ~$5.5M.","Cash $90.3M; additional $25M credit facility available, total accessible ~$115M.","2025 revenue guidance reaffirmed $205-210M; targeting first positive EBITDA quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":166025000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176335,"accession_number":"0001688757-25-000008","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2025-01-16T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Establishment Labs guides 2025 revenue $205M-$210M, positive adjusted EBITDA in 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2025 revenue guidance of $205M-$210M ($170M-$175M international, $35M US).","Expects positive adjusted EBITDA in 2025.","Expects positive cash flow in 2026.","Guidance provided at J.P. Morgan Healthcare Conference on Jan 15, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176334,"accession_number":"0001688757-25-000003","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Founder CEO Chacón-Quirós to retire March 1; 2024 revenue guidance $166M-$166.5M","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Juan José Chacón-Quirós retires effective March 1, 2025; stays on board and as advisor.","President Peter Caldini becomes Interim CEO; previously CEO of Acreage Holdings and Pfizer executive.","Preliminary 2024 revenue expected $166M-$166.5M; Q4 2024 revenue $44.5M-$45.0M.","Q4 includes approx. $3.2M from Motiva sales in the United States.","Revenue in line with prior guidance; no full earnings metrics provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193202,"accession_number":"0001688757-24-000097","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Establishment Labs extends Tranche D loan commitment to Dec 2025 and raises ~$49.8M in equity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended credit agreement: Tranche D term loan commitment termination date extended to Dec 31, 2025 from June 30, 2025.","New milestone for Tranche D availability: trailing 12-month gross sales of $195M total and $30M in US for Motiva/Flora.","Registered direct offering of 765,696 common shares at $45.71/share plus pre-funded warrants for 328,154 common shares at $45.709.","Net proceeds ~$49.8M for general corporate purposes such as sales/marketing, R&D, working capital.","Additional 10% of shares/warrants issuable if average closing price does not exceed $45.71 in Jan–Aug 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193201,"accession_number":"0001688757-24-000091","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Establishment Labs announces $50M registered direct offering and FY2024 revenue guidance of $165-168M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 765,696 common shares at $45.71/share and pre-funded warrants for 328,161 shares; total gross proceeds ~$50M.","Additional 76,569 shares and 32,815 warrant shares issuable if average closing price ≤$45.71 between Jan-Aug 2025.","FY2024 revenue expected $165-168M; FY2025 non-U.S. revenue mid-single digit growth; U.S. revenue >$35M.","Credit agreement amended: Tranche D commitment termination extended to Dec 31, 2025; milestone set at $195M trailing 12-month gross sales including $30M U.S. for Motiva.","Net proceeds to be used for sales/marketing, R&D, working capital, and capex."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193200,"accession_number":"0001688757-24-000088","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Establishment Labs Q3 revenue $40.2M, cuts 2024 guidance to $165-168M, raises $50M in direct offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $40.2M vs $38.5M YoY; net loss $16.7M vs $29.3M loss YoY; adjusted EBITDA loss $7.0M vs $16.3M loss.","2024 revenue guidance reduced to $165-168M from prior $174-184M due to FDA delay and Brazil weakness.","Cash $39.7M at Sep 30; pro forma $114M after $25M Oaktree draw and $50M registered direct offering (5% discount).","FDA approved Motiva Implants Sep 26; U.S. launch added 250+ accounts in first three weeks; expects >$35M U.S. revenue in 2025.","Oaktree facility amended: $25M Tranche D available through Dec 31, 2025 subject to revenue milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":121511000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209575,"accession_number":"0001688757-24-000084","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2024-09-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA approves Motiva SmoothSilk implants for breast augmentation; first new PMA since 2013","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approval for Motiva SmoothSilk Ergonomix and Round implants in primary and revision breast augmentation.","Three-year clinical trial data: capsular contracture 0.5%, rupture 0.6%, infection 0.9% in primary augmentation cohort.","First new breast implant PMA approved by FDA since 2013; nearly 4 million Motiva devices already delivered in 85+ countries.","CEO Juan José Chacón-Quirós calls approval transformative for U.S. breast aesthetics, citing differentiated technology.","Study conducted at 32 U.S. and 3 European centers; patient compliance at 92.4% at 3-year endpoint."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209574,"accession_number":"0001688757-24-000079","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2024-08-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Appoints Fillipo 'Peter' Caldini as President; base salary $415K, $1M equity grant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Fillipo 'Peter' Caldini as President effective August 20, 2024, reporting to CEO.","Base salary $415K; annual bonus target 50% of base; annual equity award target 100% of base.","New hire equity grant: $600K in options and $400K in RSUs, vesting over 4 years.","Previously CEO of Acreage Holdings and regional president at Pfizer Consumer Healthcare; held roles at Bayer.","Severance: 9 months salary on non-CIC termination; 12 months salary plus full bonus acceleration on CIC termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209573,"accession_number":"0001688757-24-000071","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Establishment Labs Q2 revenue $44.1M, loss narrows; FDA PMA inspection completed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $44.1M vs $48.6M YoY; gross margin improved to 65.6% from 62.3%.","Operating loss $9.3M vs $13.7M loss YoY; adjusted EBITDA loss $4.3M vs $9.3M.","Net loss $17.2M; cash $54.6M, up $14.6M from Dec 2023.","FY2024 revenue guidance reaffirmed $174M-$184M (+5-11% YoY).","FDA completed PMA preapproval inspection July 26; Motiva Implants US approval expected soon."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":81284000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209572,"accession_number":"0001688757-24-000067","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2024-07-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA PMA preapproval inspection of Establishment Labs' Motiva Implant facility rescheduled to July 22","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA will begin PMA preapproval inspection of Motiva Implants manufacturing facility on July 22, 2024.","Inspection was previously scheduled for the first week of July 2024.","Rescheduling is a procedural update; no new findings or delays beyond the date change."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227675,"accession_number":"0001688757-24-000065","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA deems Establishment Labs' Motiva Implants PMA approvable pending facility inspection","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA CDRH completed PMA review for Motiva Implants; says PMA is approvable subject to acceptable manufacturing facility inspection.","FDA inspection of manufacturing facilities rescheduled from prior dates to occur within next 30 days.","Announced June 5, 2024 at Jefferies Global Healthcare Conference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227674,"accession_number":"0001688757-24-000063","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Establishment Labs shareholders elect directors, approve say-on-pay, ratify auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ann Custin received 18,049,023 votes for, 1,659,450 against; Bryan Slotkin 18,175,945 for, 1,532,799 against.","Advisory vote on named executive officer compensation passed: 17,999,791 for, 1,708,025 against.","Ratification of Marcum LLP as auditor for FY2024: 20,177,610 for, 2,775,431 against.","Broker non-votes of 3,244,356 on director elections and say-on-pay proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227673,"accession_number":"0001688757-24-000056","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Establishment Labs reports Q1 revenue down 20% YoY; narrows operating loss sequentially; reaffirms 2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2024 revenue $37.2M (down 20% YoY from $46.5M); net loss $16.2M vs $11.9M loss in Q1 2023.","Adjusted EBITDA loss improved to $3.7M from $17.3M in Q4 2023; operating loss $8.8M vs $22.1M in Q4 2023.","Cash balance $73.0M, up $32.9M from Dec 31, 2023 due to private placement; 2024 revenue guidance reaffirmed at $174M-$184M.","Company presented 4-year Motiva US IDE study data with low capsular contracture/rupture rates; expects FDA approval in 2024.","Launched Motiva implants in China and Flora tissue expander in US; cost reduction initiatives lowered SG&A and R&D expenses."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":37167000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227672,"accession_number":"0001688757-24-000042","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2024-04-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA schedules PMA preapproval inspection of Establishment Labs' Motiva Implants facility in Q2 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA schedules PMA preapproval inspection of Motiva Implants manufacturing facility for Q2 2024.","Inspection is a required step in the premarket approval (PMA) process for U.S. market entry.","Announcement made on April 2, 2024 during J.P. Morgan MedTech CEO Conference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}